SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.840
-0.030 (-0.78%)
Mar 25, 2026, 11:56 AM EDT - Market open
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover SAB Biotherapeutics stock have a consensus rating of "Strong Buy" and an average price target of $9.80, which forecasts a 155.21% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $15.
Price Target: $9.80 (+155.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +264.58% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +82.29% | Mar 10, 2026 |
| UBS | UBS | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +82.29% | Jan 7, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +290.63% | Dec 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +212.50% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
127.50K
EPS This Year
-0.62
from -0.79
EPS Next Year
-0.48
from -0.62
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 525,000 | |||
| Avg | n/a | 127,500 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.32 | -0.26 | |||
| Avg | -0.62 | -0.48 | |||
| Low | -1.10 | -0.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.